Inventprise https://validator.w3.org/feed/docs/rss2.html Header Footer About Us Services Home Inventprise Announces Positive Interim Results from the Phase 1/2 clinical study for Hexavalent Group B Streptococcal Vaccine Candidate (IVT GBS-06) Inventprise Announces Breakthrough in COVID-19 Conjugate Vaccine Study Published in Vaccine Journal Inventprise Selects Quantoom Biosciences’ Ntensify® Production Technology to Advance mRNA Vaccine Development <em>Every Breath Counts:</em> Pneumococcal Conjugate Vaccine Scorecard 2022 Contact News & Publications Manufacturing Technology Pipeline Careers Open Positions Benefits <em>Vaccine Journal, Volume 54:</em> SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants Careers – Header Test Services Page Header Path.com: A Deadly Disease for Infants Has No Vaccine—We’re Changing That Inventprise CEO Attends 2nd Global Forum on Childhood Pneumonia Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate <em>Human Vaccines & Immunotherapies:</em> Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production Privacy Policy Pipeline-REV-11 Contract Services Pipeline – OLD CONTENT Inventprise Press Release Archive GeekWire: Seattle-Area Startup Inventprise Gets Backing from Gates Foundation for Pneumonia Shot Gates Notes: A Promising New Vaccine to Protect Children from Their #1 Killer Biospace: Gates Foundation Pours $90 Million into Promising New Pneumococcal Vaccine Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical Trials Inventprise In the News Archive Precision Vaccinations: Pneumococcal Vaccines 2023 Inventprise Inaugurates Manufacturing Facility for High-Capacity Supply of Pneumococcal Conjugate Vaccines New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation Life Science Washington Welcomes New Board Members as the State’s Life Sciences Industry Strengthens Its Position as a Top 10 US Cluster Members About Us Page Header Portfolios Custom Shop Testimonials Testimonial Page Header Pipeline-LONGTERM Pradhip Ghate, MS, MBA Inventprise Receives $30M, Appoints New CEO and Expands Corporate Board PATH: Inventprise’s Expanded-coverage Pneumococcal Vaccine Enters the Clinic Faq Page Header Poster Presentation: Preclinical Results for a 25-Valent Penumococcal Conjugate Vaccine Using A Novel Linker Platform Technology – ISPPD-12 | June, 2022